B22 Glu des-B30 insulin: a novel monomeric insulin.
Studies on monomeric insulin with reduced self-association are important in the development of insulin pharmaceutical preparations with rapid hypoglycemic action on patients with diabetes. Here we report a novel monomeric insulin, B22 Glu des-B30 insulin, prepared from a single chain insulin precursor with B22 Arg mutated to Glu, which was expressed in Pichia pastoris and converted to B22 Glu des-B30 insulin by tryptic digestion. It still retains 50% of the in vivo biological activity of porcine insulin and does not form a dimer even at a concentration of 10 mg/ml, showing that B22 Glu plays a key role in reducing the self-association of the insulin molecule without greatly reducing its biological activity. This novel monomeric insulin might have potential applications in the clinic.
Du
Hai-Juan
HJ
Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Shi
Jia-Hao
JH
Cui
Da-Fu
DF
Zhang
You-Shang
YS
D000818:Animals; D002850:Chromatography, Gel; D002942:Circular Dichroism; D007004:Hypoglycemic Agents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D007328:Insulin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D051379:Mice; D010843:Pichia / Q000235:genetics; D011498:Protein Precursors / Q000378:metabolism; D011817:Rabbits
C513189:B22 Glu des-B30 insulin; D007004:Hypoglycemic Agents; D007328:Insulin; D011498:Protein Precursors